Acute liver failure (ALF) is a rare but devastating condition that arises from diverse etiologies, has a high mortality and requires high resource utilization including transplantation.
The Acute Liver Failure Study Group (ALFSG) has been funded by NIDDK since 1997 to collect detailed clinical data on more than 3,500 patients, but will be closing its registry and database permanently in 2019. It is an opportune time to take stock, consider where the field of study of ALF is going, what has been accomplished and to determine future directions of research in this unique syndrome.
March 30-31, 2020
UT Southwestern Campus
Who should attend?
Basic scientists that work on liver injury and clinicians (hepatologists, surgeons) who care for these very ill patients.
This two day program will provide a comprehensive understanding of all aspects of the pathogenesis and treatment of ALF including possible future therapies. The initial day of the meeting will be devoted to allowing investigators to present work pertaining to pathogenesis and disease mechanisms. The second day of the meeting will be devoted to reviewing aspects of disease management including evaluation, treatment and consideration of prognosis, liver transplantation and liver support devices.
This course/program is endorsed by AASLD. The Acute Liver Failure Study Group is pleased to have received the endorsement of the American Association for the Study of Liver Diseases (AASLD). Copyright © 2020 by the American Association for the Study Diseases. All rights reserved.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of AASLD. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.